Ronald Witteles, MD, is a professor of cardiovascular medicine at Stanford University and co-director of the Stanford Amyloid Center and the Stanford Multidisciplinary Sarcoidosis Program

HELIOS-B: Open-Label Extension Proves Vutrisiran’s Long-Term Efficacy, With Ronald Witteles, MD

Vutrisiran has demonstrated significant clinical benefit in patients with 

transthyretin amyloidosis with cardiomyopathy (ATTR-CM)

 compared to placebo, based on 12-month data from an open-label extension of the HELIOS-B trial presented at the 

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025

ATTR-CM is a progressive and frequently fatal disease, characterized by deposition of misfolded transthyretin protein in the heart. Vutrisiran inhibits hepatic transthyretin production, leading to rapid knockdown of the pathogenic protein. In the HELIOS-B trial, the subcutaneously administered RNA interface therapy was shown to lower the risk of the primary composite endpoint of all-cause mortality (ACM) and recurrent cardiovascular (CV) events compared to placebo.

 sat down with Ronald Witteles, MD, co-director of the Stanford Amyloid Center and the Stanford Multidisciplinary Sarcoidosis Program at the Stanford University School of Medicine, to discuss the study and his thoughts on vutrisiran fitting into the broader ATTR-CM treatment landscape.

“We wanted to look at people who had followed for up to 12 months of open-label extension data,” Witteles told 

. “The takeaway from all of that was that vutrisiran works, it works well, and the longer that patients are on it, you will have further separation of the curves. We can also see that patients who started on placebo and then switched to the open-label extension clearly had disease progression by several markers: quality of life, cardiac biomarkers, et cetera.”

HELIOS-B was a phase 3 interventional global trial, during which 655 patients were tested across 79 locations. The trial comprised a 33-36-month double-blind period, followed by a 2-year open-label extension. Investigators included 2 arms receiving vutrisiran; the first had been taking tafamidis on baseline, and the second had not. The latter was measured separately as the monotherapy population.

To be included, patients were required to have a documented diagnosis of ATTR amyloidosis with cardiomyopathy, classified as either hereditary ATTR (hATTR) amyloidosis with cardiomyopathy or wild-type ATTR amyloidosis. Additionally, patients were required to exhibit a medical history of 

 with ≥1 before hospitalization for heart failure or clinical evidence of heart failure.

Patients were excluded from the study if they had known primary amyloidosis or leptomeningeal amyloidosis, if they had New York Heart Association Class IV heart failure or Class III heart failure and were at risk based on prespecified criteria, or had a polyneuropathy disability, among other conditions.

Primary outcomes included a composite endpoint of ACM and recurrent CV events, as well as hospitalizations and urgent heart failure visits. Secondary outcomes included change from baseline in 6-minute walk test and change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary, among others.

Patients receiving vutrisiran in the first phase of HELIOS-3 exhibited reduced risk of the primary composite endpoint in both the overall population and the monotherapy population. Patients who completed this period were eligible to enter the extension, which saw all patients receive vutrisiran 25mg Q3M. During this study, Witteles and colleagues measured mortality and CV events to determine the long-term efficacy of the drug.

Ultimately, the 466 patients in the extension study exhibited sustained improvement across key measures of disease progression through the first 12 months of the study. The long-term safety and tolerability profile was also consistent with vutrisiran’s established profile.

“If you look at the subjects who started and ended on vutrisiran, their average troponin level was a little lower all the way out at 48 months than it was at baseline. So that tells us something as well,” Witteles said. “The big take-home message is that you don’t want to wait to start therapy. That is lost functional status, it’s lost progression of disease.”

Editor's Note: Witteles reports disclosures with Alexion, Alnylam, AstraZeneca, BridgeBio, Novo Nordisk, and Pfizer.

Garcia-Pavia P, Witteles R, Morbach C, et al. HELIOS-B: 12-Month Results From the Open-Label Extension Period of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. Presented at the Heart Failure Society of America Annual Scientific Meeting 2025. Minneapolis, MN. September 26-29, 2025.

Alnylam Pharmaceuticals. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. ClinicalTrials.gov identifier: NCT04153149. Updated May 13, 2025. Accessed October 16, 2025. 

https://clinicaltrials.gov/study/NCT04153149

Alnylam Pharmaceuticals. New Data from Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM. August 31, 2025. Accessed October 16, 2025. 

https://investors.alnylam.com/press-release?id=29256

Videos

Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Credit: Amsterdam University Medical Center

Telitacicept has demonstrated markedly higher response rates compared to placebo in addition to standard therapy for people with 

 in a phase 3 trial, although accordingly higher rates of adverse events (AEs) were also observed.

“These data support the central role of B-cells in the pathobiology of lupus. By targeting both BAFF and APRIL, it was possible to achieve excellent clinical results that suggest the effective restoration of immune balance in at least some of the patients. With this mechanism of action, telitacicept could significantly reduce the burden of lupus,” Ronald van Vollenhoven, MD, PhD, Professor of Rheumatology at Amsterdam University Medical Center, said in a statement.

 “This approach could represent an important new addition to the therapeutic landscape for lupus.”

The new findings are from a phase 3 trial conducted in China, results of which were published in 

be held in Chicago, Illinois, on October 25 to 29. In the trial, participants with active SLE were randomly assigned 1:1 to receive telitacicept (160 mg) or placebo subcutaneously once weekly for 52 weeks, in addition to standard therapy. The trial primarily evaluated response on the modified SLE Responder Index 4 (SRI-4) at week 52. Response on the composite endpoint is defined as reduction of at least 4 points in the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score, no new disease activity as measured on the British Isles Lupus Assessment Group index, and no worsening in the Physician’s Global Assessment score.

The trial screen 433 adults, 335 of which underwent randomization to telitacicept (n = 167) or placebo (n = 168). Investigators found that at week 52, significantly more participants receiving telitacicept (67.1%) had a modified SRI-4 response than those receiving placebo (32.7%; adjusted difference, 34.5%; 95% CI, 24.3-44.7; 

<.001). Furthermore, 70.1% of the telitacicept group compared to 40.5% of the placebo group achieved a reduction of at least 4 points from baseline in the SELENA-SLEDAI score (difference, 29.6%; 95% CI, 13.1-46.1).

Investigators did observe significant differences in the safety profiles between the placebo and telitacicept groups. The telitacicept group had a higher incidence (74.9%) of AEs considered related to treatment then placebo (50%), including upper respiratory tract infections (31.7% vs. 19.0%), a reduced serum IgG level (15.6% vs. 1.2%), reduced serum IgM levels (15.0% vs. 0.6%), and injection-site reactions (12.6% vs. 0.6%).

“We are humbled by what these results represent for patients and the scientific community, and by the recognition that comes with their publication in The New England Journal of Medicine, which underscores the global acceptance of the quality and rigor of clinical research emerging from China. For the first time, a therapy in a Phase 3 trial is delivering more than double the clinical response seen with the current standard of care in lupus. These data present a compelling case for potentially broadening telitacicept’s use as a new standard of care worldwide,” Jean-Paul Kress, MD, Chief Executive Officer and Chairman of Vor Bio, added.

 “Lupus has challenged researchers and clinicians for decades. To see a dual BAFF/APRIL approach deliver this level of efficacy, durability, and consistency across multiple indications, while maintaining a favorable safety profile, affirms our belief that telitacicept has the potential to redefine how autoimmune diseases are treated.”

Vor Bio has also announced that findings from another phase 3 trial of telitacicept conducted in China, in people with primary Sjögren disease, will be presented at the upcoming American College of Rheumatology meeting in a late-breaking abstract. The meeting will be held in Chicago, Illinois, from October 25-29.

van Vollenhoven RF, Wang L, Merrill JT, et al. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. 

. 2025;393(15):1475-1485. doi:10.1056/NEJMoa2414719

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine. News release. Vor Biopharma. October 16, 2025. 

https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025. News release. Vor Biopharma. October 14, 2025. https://www.globenewswire.com/news-release/2025/10/14/3166097/0/en/Telitacicept-Demonstrates-Clinically-Meaningful-and-Statistically-Significant-Impact-on-ESSDAI-Compared-to-Placebo-in-Late-Breaking-China-Phase-3-Results-in-Primary-Sj%C3%B6gren-s-Disea.html

Articles

Telitacicept has shown significantly higher response rates than placebo in a phase 3 trial for systemic lupus erythematosus (SLE), although it also resulted in increased adverse events. The trial, conducted in China, demonstrated telitacicept's efficacy in reducing disease activity and improving clinical outcomes by targeting BAFF and APRIL. Despite the higher incidence of adverse events, the results suggest telitacicept could become a new standard of care for lupus. Further research is ongoing, including trials for primary Sjögren's disease.

However, a notable higher rate of treatment-related adverse events warrants caution.

Lupus

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Telitacicept Significantly Improves Lupus Response Rates Above SOC Alone 

Aguh is an associate professor of dermatology and the director of the Ethnic Skin Program at the Johns Hopkins School of Medicine.

Loren Krueger, MD, is a board-certified dermatologist specializing in hair loss and an assistant professor at Emory School of Medicine.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Skin of Color Savvy: The Science of Curly Hair, With Crystal Aguh, MD, and Loren Krueger, MD

, dermatologists Crystal Aguh, MD, and Loren Krueger, MD, explored the biological, cultural, and clinical considerations behind curly and coily hair patterns. This podcast by 

, features a discussion underscoring the ways in which textured hair care represents a critical—and often overlooked—component of dermatologic expertise.

Curly hair is inherently more fragile than straight hair, with structural features that make it prone to dryness, breakage, and inflammation-related disease. According to Aguh, this fragility parallels the challenges of dry skin: without proper moisture retention and care, minor issues can progress into medical disease. For dermatologists, understanding textured hair is therefore not elective—it is essential to preventing conditions such as traction alopecia, acquired trichorrhexis nodosa, and central centrifugal cicatricial alopecia (CCCA).

Krueger emphasized that nearly every form of alopecia—from androgenetic to autoimmune variants—can present in patients with curly hair, but diagnostic precision requires recognizing when styling practices contribute to disease. She noted that effective management involves more than identifying pathology; it requires guiding patients toward healthier styling behaviors while respecting their cultural identities and lifestyle constraints.

For clinicians unfamiliar with curly hair care, Aguh recommended starting with the basics—what she calls a “soak and smear” method for the hair, analogous to the technique used for eczema management. Patients should be advised to cleanse weekly with a non-drying shampoo, condition regularly, and seal in moisture with a leave-in product, oil, or emollient. These steps help reinforce the hair cuticle and prevent cumulative damage that predisposes to breakage.

The conversation also addressed styling practices frequently described as “protective,” such as braids, twists, and sew-in weaves. Both dermatologists noted that these should instead be viewed as “styles of convenience”—useful in moderation but potentially harmful if worn too tightly or for extended periods. Appropriate guidance includes limiting braided styles to six to eight weeks, avoiding back-to-back installations, and recognizing that tightness and scalp pain are early indicators of follicular injury.

Age-related hair fragility and chemical exposure further complicate outcomes. Patients accustomed to long-standing styling routines often underestimate how aging, coloring, or relaxing can weaken the hair over time. Dermatologists must therefore distinguish between true hair loss and breakage-related thinning to prevent unnecessary laboratory testing or scalp biopsies.

Ultimately, the “science of curls” reflects the intersection of biology, identity, and daily care. By integrating practical knowledge of hair texture into routine dermatologic evaluation, clinicians can enhance outcomes, foster trust, and deliver more culturally responsive care for all patients.

To learn more about SOCS’s mentorship programs and initiatives, visit 

This October 16 Skin of Color Savvy highlights the often overlooked topic of curly hair in dermatology.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A recent study showed that magnetic seizure therapy offered comparable efficacy to modified electroconvulsive therapy (ECT) with superior cognitive protection and safety in adolescents with 

“While [ECT] outperformed [magnetic seizure therapy] in BDI-II reduction…reflecting its rapid antidepressant action, [magnetic seizure therapy’s] superiority in cognitive preservation – evidenced by [Montreal Cognitive Assessment] total score improvement…and specific gains in memory, orientation, and executive function – highlights its potential to safeguard neurodevelopment in this vulnerable group,” wrote investigator Wei Wang, from Shandong Mental Health Center, and colleagues.

ECT is an effective, often lifesaving treatment for MDD but can cause cognitive side effects like memory impairment, which may be especially harmful to adolescents. Conversely, magnetic seizure therapy uses high-frequency magnetic stimulation to induce seizures while sparing deeper brain structures, like the hippocampus, potentially reducing cognitive effects. Early studies suggest magnetic seizure therapy provides similar efficacy to ECT with less cognitive impact, though adolescent data remain limited.

Investigators conducted a prospective, assessor-blinded randomized controlled trial between March 1 and April 30, 2025, at Shandong Mental Health Center to compare magnetic seizure therapy with modified ECT for adolescent MDD in terms of cognitive protection and suicidality improvement.

The primary outcome was the Beck Depression Inventory-II (BDI-II) percentage reduction, and secondary outcomes included Montreal Cognitive Assessment scores (total score and subdomains of visuospatial/executive function, naming, attention, language, abstraction, memory, orientation), Columbia-Suicide Severity Rating Scale, and adverse events per CTCAE 5.0, and reorientation time. Investigators assessed these outcomes at baseline and 7 days post-treatment.

The sample included 120 adolescents aged 13 – 18 years with treatment-resistant MDD (baseline BDI-II ≥ 29). The study excluded participants with comorbid bipolar disorder or schizophrenia, intracranial metal implants, epilepsy, severe physical illness, or prior exposure to either therapy.

Investigators randomized participants 1:1 to receive magnetic seizure therapy (n = 60; mean age, 15.15 years; 78.33% females) or modified ECT (n = 60; mean age, 15.20 years; 80% females) for 12 – 16 sessions, 3 times weekly. Magnetic seizure therapy used the NS7000 device with stimulation at the Cz position, 100 Hz frequency, 100% intensity, and 8 – 10 seconds per second. Meanwhile, the modified ECT used the Thymatron System IV, with bilateral stimulation dosed according to age. Participants received anesthesia (propofol 1.5 – 20 mg and succinylcholine 0.5 mg/kg) and continued SSRIs without benzodiazepines or mood stabilizers.

Modified ECT led to greater BDI-II reductions (51.8% vs 46.5%; 

<.001), with similar response rates between treatments (90.0% vs 91.1%; 

 =.081). However, magnetic seizure therapy showed significant improvements in the total cognitive score (difference, 1.32; 95% confidence interval [CI], 0.92 – 1.70; 

 <0.001), especially in memory (difference, 1.20; 95% CI, 0.99 – 1.41; 

<.001), orientation (difference, 0.66; 95% CI, 0.45 – 0.87; 

 <.001), and executive function subdomains (difference, 0.50; 95% CI, 0.35 – 0.65; 

 <.001). The study reported lower subjective cognitive complaints in the magnetic seizure therapy arm (20% vs 62%; 

Magnetic seizure therapy also improved suicidality outcomes more effectively (4.91±0.29 to 0.78±0.90 vs. 4.98±0.14 to 1.12±0.69; 

 =.036), with a greater remission rate (33.3% vs. 16.0%; 

 =.044). The study found no significant group difference regarding severity scores (

Investigators observed a stronger correlation between Montreal Cognitive Assessment change and suicidality improvement in magnetic seizure therapy (95% CI, 0.48 – 0.74, 

 =.008). The mediation analysis demonstrated a partial mediating role of Montreal Cognitive Assessment improvement in magnetic seizure therapy (95% CI, 0.10 - 0.54;

Safety findings favored magnetic seizure therapy, with fewer adverse events (28.9% vs 64.0%; 

 <.001) and shorter reorientation time (6.9±1.8 vs 18.7±6.8 minutes; 

 <.001). Adverse events included short-term memory loss (20.0% vs. 62.0%; 

“[Magnetic seizure therapy] offers a balanced treatment for adolescent MDD, matching [modified ECT’s] antidepressant efficacy while excelling in cognitive protection and suicidality reduction,” investigators concluded.

 “The mediating role of cognitive improvement suggests a novel mechanism, positioning [magnetic seizure therapy] as a promising option for preserving neurodevelopment and mitigating suicide risk. Long-term, multicenter trials are needed to optimize its clinical application.”

Wang W, Lu Y, Mi GL, Li XJ, Zhang DN, Qi SF. Cognitive preservation advantage and efficacy balance of magnetic seizure therapy in adolescent Major Depressive Disorder: a randomized controlled trial revealing efficacy cognition decoupling phenomenon. 

. 2025;60(5):196-201. doi:10.1708/4583.45901

Chen S, Sheng J, Yang F, et al. Magnetic Seizure Therapy vs Modified Electroconvulsive Therapy in Patients With Bipolar Mania: A Randomized Clinical Trial. 

. 2024;7(4):e247919. Published 2024 Apr 1. doi:10.1001/jamanetworkopen.2024.7919

Deng ZD, Luber B, McClintock SM, Weiner RD, Husain MM, Lisanby SH. Clinical Outcomes of Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode: A Randomized Clinical Trial. 

. 2024;81(3):240-249. doi:10.1001/jamapsychiatry.2023.4599

A study compared magnetic seizure therapy to modified electroconvulsive therapy (ECT) in adolescents with major depressive disorder (MDD), finding similar efficacy but superior cognitive protection with magnetic seizure therapy. While ECT showed greater reduction in depression scores, magnetic seizure therapy excelled in cognitive preservation, particularly in memory, orientation, and executive function. It also demonstrated better outcomes in suicidality reduction and fewer adverse events. The study suggests magnetic seizure therapy as a promising treatment for adolescent MDD, emphasizing the need for further long-term, multicenter trials to optimize its clinical application.

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD

Subhash Banerjee, MD, is an interventional cardiologist with Baylor Scott & White.

FDA Clears Santreva-ATK for Patients with Peripheral Artery Disease With Subhash Banerjee, MD

On September 29, 2025, parent company AngioSafe revealed multiple clinical milestones achieved by its Santreva-ATK Endovascular Revascularization Catheter, including 510(k) clearance from the 

Santreva-ATK is the first wire-free, external power-free, intraplaque chronic total occlusion (CTO) crossing and 1-step vessel preparation platform for femoropopliteal arteries. The device is intended for use in patients with 

 exhibiting CTOs, which are encountered up to 50% of the time in patients with symptomatic PAD. These lesions are a leading cause of failed interventions, prolonged procedure times, and adverse events. Current tools for managing CTOs are limited, leaving clinicians with relatively few methods of treatment.

These approvals are a product of positive results from the RESTOR-1 clinical trial, which investigated the device’s efficacy in treating patients with CTOs in PAD. Santreva-ATK successfully crossed CTOs in 90% of participants, compressing plaque and recanalizing CTOs to prepare vessels for further imaging and final treatment.

 sat down with lead investigator Subhash Banerjee, MD, an interventional cardiologist with Baylor Scott & White, to discuss the implications of this new technology and how it will relieve the burden of this underserved patient population.

“In this study, which is very unique to any study done before in the CTO space in PAD, we were not only studying whether we crossed the blockage successfully, but also how we crossed,” Banerjee told 

. “Did we cross through the center of the plaque or the body of the blockage? In doing so, did we damage or tear the walls of the blood vessel that we are crossing?”

RESTOR-1 was a prospective, multi-center, pivotal study conducted across 14 sites in the US. For inclusion, patients had to be ≥22 years of age, have PAD of category 2-5 as defined by Rutherford Clinical Classification, and have PAD in the target extremity confirmed via imaging and/or magnetic resonance angiography (MRA). Patients were excluded if they exhibited systemic infection or an infection in the same extremity as the target lesion, if the lesion was within a native vein, synthetic vessel grafts, or stent occlusion, or if the patient had plans for an intervention in the contralateral limb or target limb during the study, among other conditions.

A total of 133 patients were ultimately enrolled in the trial; each participant was treated with Santreva-ATK, which facilitated the intraluminal placement of guidewires beyond CTOs in the peripheral vasculature. Outcome measures included the ability of the catheter to place the guidewire in the absence of device-related major adverse events through discharge or 24 hours post-operation, whichever came first.

Investigators found a mean CTO crossing time of 25 minutes between all patients, with a median of 9 minutes. The trial exhibited a 90% success rate with a mean Lumen gain of >55%. Investigators recorded no device-related MAEs or embolization, as well as no major perforations, flow-limiting dissections, or bailout stents. Significant improvements in Rutherford Classification and pain scores were also recorded.

“The implications can be very profound,” Banerjee said. “The greatest contribution of this technology, in my view, would be to democratize peripheral CTO procedures. That means operators at various stages in their lives or careers can take on these procedures and help more patients because of a combination of higher success and, importantly, not causing any major serious complications in the patients.”

According to a press release from AngioSafe, Santreva-ATK is planned to launch in the US in October of 2025. Highlights from the RESTOR-1 results was presented at the Amputation Prevention Symposium Europe Congress on October 14, 2025.

Editor's Note: Banerjee reports disclosures with AngioSafe, Esperion, GE Healthcare, Kaneka, Teleflex, Ca

AngioSafe Unveils Atheroplasty Innovation Following DA 501(k) Clearance, CE Mark Approval, and First Real-World Procedures with Santreva-ATK Endovascular Revascularization Catheter. September 29, 2025. Accessed October 16, 2025. 

https://www.angiosafe.com/press-releases/angiosafe-unveils-atheroplasty-innovation-following-fda-510k-clearance-ce-mark-approval-and-first-real-world-procedures-with-santreva-atk-endovascular-revascularization-catheter/

AngioSafe, Inc. AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study) (RESTOR-1). ClinicalTrials.gov identifier: NCT04663867. Updated November 4, 2024. Accessed October 16, 2025. 

https://www.clinicaltrials.gov/study/NCT04663867

Santreva-ATK, the first wire-free endovascular revascularization catheter for crossing chronic total occlusions, is expected to begin sale in October 2025.

FDA News

FDA Clears Santreva-ATK for Patients with Peripheral Artery Disease, With Subhash Banerjee, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Final results from APPLAUSE-IgAN demonstrate iptacopan’s superiority versus placebo for slowing IgAN progression and will be used to support its full approval.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

APPLAUSE-IgAN: Iptacopan (Fabhalta) Meets eGFR Decline Primary Endpoint

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.


Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

ALLEGRO-2b/3: Post-Hoc Analysis Suggests Alopecia Areata Improves With Ritlecitinib

Panelists discuss how the 2 approved IL-17 inhibitors—secukinumab (IL-17A) and bimekizumab (IL-17A/F)—differ in their mechanisms, with bimekizumab potentially offering faster responses and greater impact on drainage but higher cutaneous adverse effects, while secukinumab provides a slightly better skin safety profile with slower but sustained improvement.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

IL-17 Inhibitors in HS Practice

A 5-year follow-up showed 76% of delabeled children reused the previously avoided antibiotic without significant adverse reactions.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Most Children Safely Reuse Antibiotics 5 Years After Allergy Delabeling

Panelists discuss how IL-17 emerged as a key inflammatory driver in HS pathophysiology, with IL-17 inhibitors offering strong efficacy and favorable safety profiles compared with TNF inhibitors, making them increasingly preferred as first-line biologic therapy except in patients with inflammatory bowel disease.

Role of IL-17 Inhibition in HS

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers

In this episode, sisters and dermatologists Mona and Neda Shahriari discuss mentorship, motherhood, and the meaning of sisterhood in medicine.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: Leadership and Sisterhood in Dermatology, With Neda Shahriari, MD

Ahmad Masri, MD, MS, is the director of the Hypertrophic Cardiomyopathy Center at Oregon Health and Science University. 

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ATTRibute-CM: Acoramidis Reduces Cardiovascular Mortality and Hospitalization, With Ahmad Masri, MD

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

APPEAR-C3G: Iptacopan Shows Proteinuria Reduction, eGFR Benefits in C3G

A phase 1b/2a study showed CM326 significantly improved nasal polyp scores; baseline plasma TSLP levels ≥ 330 fg/mL may predict treatment response.


Latest News

HELIOS-B: Open-Label Extension Proves Vutrisiran’s Long-Term Efficacy, With Ronald Witteles, MD

Telitacicept Significantly Improves Lupus Response Rates Above SOC Alone

Skin of Color Savvy: The Science of Curly Hair, With Crystal Aguh, MD, and Loren Krueger, MD

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD

FDA Clears Santreva-ATK for Patients with Peripheral Artery Disease, With Subhash Banerjee, MD